Myriad Genetics Company Leadership
MYGN Stock | USD 12.91 0.37 2.95% |
Myriad Genetics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Myriad Genetics suggests that virtually all insiders are panicking. Myriad Genetics employs about 2.7 K people. The company is managed by 18 executives with a total tenure of roughly 18 years, averaging almost 1.0 years of service per executive, having 150.0 employees per reported executive.
Mark Verratti President President-President Assurex Health |
Myriad Genetics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-10-11 | Paul J Diaz | Disposed 15000 @ 22.93 | View | ||
2024-09-09 | Heinrich Dreismann | Disposed 10000 @ 27.05 | View | ||
2024-09-03 | Colleen F Reitan | Disposed 46012 @ 27.95 | View | ||
2024-06-03 | Daniel K Spiegelman | Disposed 3788 @ 22.04 | View | ||
2024-05-15 | Paul J Diaz | Disposed 75000 @ 25.07 | View | ||
2024-05-13 | Paul J Diaz | Disposed 57844 @ 25.13 | View |
Monitoring Myriad Genetics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Myriad |
Myriad Genetics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Myriad Genetics' future performance. Based on our forecasts, it is anticipated that Myriad will maintain a workforce of about 1000000 employees by March 2025.Myriad Genetics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0535) % which means that it has lost $0.0535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.164) %, meaning that it created substantial loss on money invested by shareholders. Myriad Genetics' management efficiency ratios could be used to measure how well Myriad Genetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of January 2025, Return On Tangible Assets is likely to grow to -0.44. In addition to that, Return On Capital Employed is likely to grow to -0.22. At this time, Myriad Genetics' Non Current Assets Total are very stable compared to the past year. As of the 30th of January 2025, Non Currrent Assets Other is likely to grow to about 14.6 M, while Total Assets are likely to drop about 670.7 M.As of the 30th of January 2025, Common Stock Shares Outstanding is likely to drop to about 75 M. In addition to that, Net Income Applicable To Common Shares is likely to drop to about 159.7 M
Myriad Genetics Workforce Comparison
Myriad Genetics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 84,505. Myriad Genetics holds roughly 2,700 in number of employees claiming about 3% of equities under Health Care industry.
Myriad Genetics Profit Margins
The company has Profit Margin (PM) of (0.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.08) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.08.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.94 | 0.79 |
|
|
Myriad Genetics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Myriad Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Myriad Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Myriad Genetics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.3333 | 2 | 6 | 23,934 | 55,908 |
2024-09-01 | 0.0833 | 1 | 12 | 61,771 | 169,160 |
2024-06-01 | 0.7778 | 7 | 9 | 109,865 | 244,217 |
2024-03-01 | 0.3929 | 11 | 28 | 748,291 | 131,318 |
2023-12-01 | 0.0833 | 1 | 12 | 236,360 | 98,140 |
2023-09-01 | 0.2222 | 2 | 9 | 20,000 | 88,962 |
2023-06-01 | 2.6667 | 8 | 3 | 113,632 | 9,979 |
2023-03-01 | 0.2941 | 10 | 34 | 436,701 | 161,474 |
2022-12-01 | 0.0769 | 1 | 13 | 16,875 | 63,143 |
2022-06-01 | 2.75 | 11 | 4 | 156,736 | 8,193 |
2022-03-01 | 1.3571 | 19 | 14 | 791,589 | 69,695 |
2021-12-01 | 0.3077 | 4 | 13 | 35,896 | 52,107 |
2021-09-01 | 0.4638 | 32 | 69 | 1,336,551 | 1,240,627 |
2021-06-01 | 0.9048 | 19 | 21 | 249,650 | 301,674 |
2021-03-01 | 1.75 | 21 | 12 | 581,430 | 204,588 |
2020-12-01 | 17.0 | 17 | 1 | 415,309 | 2,218 |
2020-09-01 | 0.3556 | 16 | 45 | 1,241,326 | 299,913 |
2020-03-01 | 0.5 | 1 | 2 | 100,000 | 11,627 |
2019-12-01 | 12.0 | 12 | 1 | 107,663 | 1,307 |
2019-09-01 | 0.2881 | 17 | 59 | 684,500 | 490,808 |
2018-12-01 | 3.0 | 6 | 2 | 56,160 | 3,327 |
2018-09-01 | 0.2963 | 16 | 54 | 724,672 | 532,684 |
2018-06-01 | 0.5714 | 16 | 28 | 336,139 | 593,124 |
2018-03-01 | 0.4375 | 7 | 16 | 158,994 | 334,593 |
2017-12-01 | 1.1667 | 7 | 6 | 50,533 | 27,553 |
2017-09-01 | 0.2857 | 10 | 35 | 535,000 | 230,757 |
2017-03-01 | 3.0 | 3 | 1 | 6,000 | 2,631 |
2016-12-01 | 6.0 | 6 | 1 | 90,144 | 3,522 |
2016-09-01 | 0.6364 | 14 | 22 | 488,598 | 131,487 |
2016-06-01 | 0.5 | 5 | 10 | 50,619 | 99,256 |
2015-12-01 | 0.8333 | 20 | 24 | 292,899 | 436,655 |
2015-09-01 | 0.4146 | 17 | 41 | 615,828 | 543,148 |
2015-06-01 | 1.0 | 1 | 1 | 5,555 | 5,555 |
2015-03-01 | 0.6 | 3 | 5 | 45,555 | 35,275 |
2014-12-01 | 1.6 | 16 | 10 | 129,555 | 37,447 |
2014-09-01 | 0.8333 | 20 | 24 | 345,103 | 367,565 |
2014-06-01 | 0.5625 | 18 | 32 | 416,500 | 687,803 |
2014-03-01 | 0.5738 | 35 | 61 | 873,906 | 1,548,485 |
2013-12-01 | 1.125 | 9 | 8 | 219,856 | 110,214 |
2013-06-01 | 0.5714 | 12 | 21 | 305,649 | 501,360 |
2012-12-01 | 0.6212 | 41 | 66 | 735,982 | 1,133,972 |
2012-09-01 | 0.7778 | 42 | 54 | 2,019,107 | 546,830 |
2012-06-01 | 0.6 | 9 | 15 | 120,389 | 223,836 |
2012-03-01 | 0.8209 | 55 | 67 | 790,442 | 655,004 |
2011-12-01 | 3.0 | 6 | 2 | 180,000 | 1,466 |
2011-09-01 | 13.0 | 13 | 1 | 1,710,808 | 5,808 |
2011-06-01 | 0.6444 | 29 | 45 | 387,914 | 565,148 |
2010-12-01 | 0.8333 | 5 | 6 | 150,000 | 133,536 |
2010-09-01 | 15.0 | 15 | 1 | 695,000 | 5,000 |
2010-06-01 | 1.0 | 4 | 4 | 28,510 | 28,510 |
2010-03-01 | 1.3 | 26 | 20 | 680,010 | 242,181 |
2009-12-01 | 0.6111 | 11 | 18 | 239,754 | 380,900 |
2009-09-01 | 2.2222 | 20 | 9 | 671,878 | 148,893 |
2009-06-01 | 1.0 | 6 | 6 | 44,936 | 79,636 |
2009-03-01 | 0.8367 | 41 | 49 | 551,753 | 353,797 |
2008-12-01 | 0.7692 | 10 | 13 | 103,000 | 70,215 |
2008-09-01 | 0.9412 | 32 | 34 | 464,602 | 208,524 |
2008-06-01 | 0.6667 | 2 | 3 | 3,550 | 3,600 |
2008-03-01 | 1.3571 | 19 | 14 | 350,310 | 57,070 |
2007-12-01 | 0.2857 | 44 | 154 | 145,600 | 188,345 |
2007-09-01 | 0.4444 | 44 | 99 | 323,471 | 180,389 |
2007-06-01 | 0.1 | 3 | 30 | 38,750 | 116,721 |
2007-03-01 | 1.3333 | 20 | 15 | 198,526 | 67,903 |
2006-12-01 | 0.5 | 6 | 12 | 65,000 | 75,225 |
2006-06-01 | 0.5714 | 4 | 7 | 65,382 | 119,566 |
2006-03-01 | 1.0 | 31 | 31 | 289,730 | 172,830 |
2005-12-01 | 1.0 | 1 | 1 | 350.00 | 350.00 |
2005-06-01 | 0.0286 | 1 | 35 | 7,500 | 187,479 |
2005-03-01 | 2.4 | 12 | 5 | 207,000 | 17,899 |
2004-12-01 | 2.5 | 5 | 2 | 75,000 | 11,853 |
2004-09-01 | 2.6667 | 8 | 3 | 193,739 | 18,739 |
2004-06-01 | 1.5 | 3 | 2 | 17,610 | 8,530 |
2004-03-01 | 11.0 | 11 | 1 | 142,000 | 5,200 |
2003-12-01 | 2.5 | 5 | 2 | 60,490 | 490.00 |
Myriad Genetics Notable Stakeholders
A Myriad Genetics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Myriad Genetics often face trade-offs trying to please all of them. Myriad Genetics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Myriad Genetics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Paul JD | President CEO | Profile | |
Paul Diaz | President CEO | Profile | |
Mark Verratti | President-President Assurex Health | Profile | |
Bryan Riggsbee | CFO, Executive VP and Treasurer | Profile | |
Justin Hunter | Interim Secretary | Profile | |
Nicole Lambert | Chief Officer | Profile | |
Jennifer Fox | Chief Officer | Profile | |
Clivetty Martinez | Chief Officer | Profile | |
Pamela Wong | Chief Officer | Profile | |
Shereen Solaiman | Chief Officer | Profile | |
Samraat Raha | Chief Officer | Profile | |
Natalie Munk | Principal Officer | Profile | |
Scott Leffler | Chief Officer | Profile | |
Scott Gleason | IR Contact Officer | Profile | |
Dale Muzzey | Chief Officer | Profile | |
Kevin Haas | Chief Officer | Profile | |
Matthew Scalo | Senior Relations | Profile | |
Glenn Farrell | Senior Officer | Profile |
About Myriad Genetics Management Performance
The success or failure of an entity such as Myriad Genetics often depends on how effective the management is. Myriad Genetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Myriad management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Myriad management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.47) | (0.44) | |
Return On Capital Employed | (0.23) | (0.22) | |
Return On Assets | (0.21) | (0.20) | |
Return On Equity | (0.30) | (0.29) |
Myriad Genetics Workforce Analysis
Traditionally, organizations such as Myriad Genetics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Myriad Genetics within its industry.Myriad Genetics Manpower Efficiency
Return on Myriad Genetics Manpower
Revenue Per Employee | 279K | |
Revenue Per Executive | 41.8M | |
Net Loss Per Employee | 97.5K | |
Net Loss Per Executive | 14.6M | |
Working Capital Per Employee | 58.4K | |
Working Capital Per Executive | 8.8M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth 0.112 | Return On Assets | Return On Equity |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.